Catalyst Pharmaceuticals, Inc stock page - price, fundamentals, dividends - iOCharts

CPRX

4.85
-0.20 (-3.96%)
Catalyst Pharmaceuticals, Inc (NASDAQ, USD)
Healthcare >
Biotechnology
Market cap
501.32M
Ent value
392.55M
Price/Sales
4.21
Price/Book
2.81
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
6.69
Forward P/E
11.28
PEG
-
EPS growth
26.50%
1 year return
44.35%
3 year return
16.09%
5 year return
37.41%
10 year return
10.92%
Last updated: 2021-09-20

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open4.98
Daily high5.01
Daily low4.81
Daily Volume984K
All-time high7.43
1y analyst estimate7.50
Beta1.29
EPS (TTM)0.72
Dividend per share-
Ex-div date-
Next earnings date8 Nov 2021

Downside potential

Loading...
Downside potential data
CPRXS&P500
Current price drop from All-time high-34.72%-4.23%
Highest price drop-94.25%-56.47%
Date of highest drop12 Nov 20129 Mar 2009
Avg drop from high-63.24%-11.47%
Avg time to new high743 days12 days
Max time to new high3146 days1805 days

DIVIDENDS

CPRX does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E6.69
Price to OCF11.13
Price to FCF11.14
Price to EBITDA11.72
EV to EBITDA9.18

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.21
Price to Book2.81
EV to Sales3.30

FINANCIALS

Per share

Loading...
Per share data
Current share count103.36M
EPS (TTM)0.72
FCF per share (TTM)0.43

Income statement

Loading...
Income statement data
Revenue (TTM)119.07M
Gross profit (TTM)102.03M
Operating income (TTM)41.30M
Net income (TTM)74.98M
EPS (TTM)0.72
EPS (1y forward)0.43

Margins

Loading...
Margins data
Gross margin (TTM)85.69%
Operating margin (TTM)34.69%
Profit margin (TTM)62.97%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash127.33M
Net receivables6.77M
Total current assets161.53M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment4.25M
Total assets197.22M
Accounts payable14.44M
Short/Current long term debt4.25M
Total current liabilities14.44M
Total liabilities18.57M
Shareholder's equity178.65M
Net tangible assets178.65M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)45.03M
Capital expenditures (TTM)34.19K
Free cash flow (TTM)45.00M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity44.21%
Return on Assets38.98%
Return on Invested Capital44.21%
Cash Return on Invested Capital26.53%
COMPANY DETAILS
CPRX (Catalyst Pharmaceuticals, Inc) company logo
Marketcap
501.32M
Marketcap category
Small-cap
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Employees
74
SEC filings
CEO
Patrick McEnany
Country
USA
City
Coral Gables
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
September 17, 2021
CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, ...
September 10, 2021
CORAL GABLES, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, ...
September 8, 2021
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
August 16, 2021
CORAL GABLES, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, d...
August 9, 2021
Catalyst (CPRX) delivered earnings and revenue surprises of 77.78% and 16.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
August 9, 2021
-Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth -Q2 2021 GAAP Net Income of $12.2 Million; Non-GAAP Net Income of $17.4 Million -$155.3 Million in Cash and Inve...
August 2, 2021
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
July 26, 2021
CORAL GABLES, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, d...
July 23, 2021
A look at the shareholders of Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) can tell us which group is most powerful...
July 19, 2021
New patent bolsters intellectual property protection for Firdapse®First in a family of four pending patents for Firdapse® to issue CORAL GABLES, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharma...
Next page